Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosingTest Category: Pharmacogenomic (Treatment) | Zendy

Daurice A. Grossniklaus | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosingTest Category: Pharmacogenomic (Treatment)

Author(s) -

Daurice A. Grossniklaus

Publication year - 2010

Publication title -

plos currents

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.282

H-Index - 49

ISSN - 2157-3999

DOI - 10.1371/currents.rrn1155

Subject(s) - vkorc1 , warfarin , vitamin k epoxide reductase , cyp2c9 , dosing , pharmacogenomics , medicine , pharmacology , cytochrome p450 , atrial fibrillation , metabolism

Warfarin is an oral anticoagulant that is widely prescribed to prevent thromboembolic events in persons at increased risk. The optimal dose is difficult to establish because it can vary 10-fold among individuals due to clinical and demographic factors. Testing for variants of the vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) genes has been proposed for use in guiding the initial dose of warfarin, thus achieving optimal dosing more quickly and with lower risk of bleeding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research